Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Inclusion Criteria: * Age ≥ 18 years * Provision of written informed consent * Histologically or cytologically documented advanced or metastatic solid tumor that is refractory to standard treatment, for which no standard therapy is available, or for which the subject refuses standard therapy * Life expectancy \> 3 months in the opinion of the investigator * ECOG performance status 0 to 1 * Evaluable OR measurable disease by RECIST 1.1 criteria * Agree to the use of effective contraceptive if either male or female of child bearing potential Exclusion Criteria: * Inadequate venous access * Women who are lactating/breastfeeding * Women with a positive pregnancy test or who are planning to become pregnant during the duration of the study * Known to be HIV positive, or have chronic hepatitis B or C * Major surgical procedure within 6 weeks of Baseline or surgical or other wound that is not fully healed at Baseline * Untreated or symptomatic brain metastasis, known central nervous system metastasis, or spinal cord compression (except glioblastoma multiforme) * Mediastinal or cavitated, or lung mass located near, invading or encasing a major blood vessel or airway on imaging * Squamous cell lung cancer * History of or known/suspected gastrointestinal perforation * Hemoptysis of \>2.5 mL (half a teaspoon) red blood within 28 days of Screening * Deep venous thrombosis or history of symptomatic pulmonary thromboembolism within 6 months of Screening * Gastrointestinal bleeding requiring medical intervention within 28 days of Screening * Receipt of therapeutic concentrations of warfarin or other anticoagulants within 7 days of Screening * Receipt of investigational agent(s) for any indication within 28 days of Baseline or 5 half lives, whichever is greater * Receipt of the following treatments: * Traditional cytotoxics, tyrosine kinase inhibitors or other small molecule anti-cancer agents within 21 days * Nitrosoureas, mitomycin C, bevacizumab or trastuzumab within 6 weeks * Any other therapeutic monoclonal antibodies within 21 days * Hormonal therapy (other than gonadal suppression) within 14 days * Radiotherapy: * to \>25% bone marrow * to brain within 28 days of baseline * other than above within 14 days of baseline * Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of Screening * History of CNS hemorrhage, cerebrovascular hemorrhage, myocardial infarction or reversible posterior leukoencephalopathy syndrome associated with prior anti-VEGF/anti-VEGFR therapy * Uncontrolled hypertension of ≥ CTCAE Grade 2 * Proteinuria at Baseline of ≥2+ or 1.0g/24 hours * Prior allergic reaction to a monoclonal antibody